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Summary
Background—A clinical decision support system (CDSS) is a computer program that applies a 
set of rules to data stored in electronic health records to offer actionable recommendations. We 
aimed to establish whether a CDSS that supports detection of immunological treatment failure 
among patients with HIV taking antiretroviral therapy (ART) would improve appropriate and 
timely action.
Methods—We did this prospective, cluster randomised controlled trial in adults and children 
(aged ≥18 months) who were eligible for, and receiving, ART at HIV clinics in Siaya County, 
western Kenya. Health facilities were randomly assigned (1:1), via block randomisation (block 
size of two) with a computer-generated random number sequence, to use electronic health records 
either alone (control) or with CDSS (intervention). Facilities were matched by type and by number 
of patients enrolled in HIV care. The primary outcome measure was the difference between groups 
in the proportion of patients who experienced immunological treatment failure and had a 
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documented clinical action. We used generalised linear mixed models with random effects to 
analyse clustered data. This trial is registered with ClinicalTrials.gov, number NCT01634802.
Findings—Between Sept 1, 2012, and Jan 31, 2014, 13 clinics, comprising 41 062 patients, were 
randomly assigned to the control group (n=6) or the intervention group (n=7). Data collection at 
each site took 12 months. Among patients eligible for ART, 10 358 (99%) of 10 478 patients were 
receiving ART at control sites and 10 991 (99%) of 11 028 patients were receiving ART at 
intervention sites. Of these patients, 1125 (11%) in the control group and 1342 (12%) in the 
intervention group had immunological treatment failure, of whom 332 (30%) and 727 (54%), 
respectively, received appropriate action. The likelihood of clinicians taking appropriate action on 
treatment failure was higher with CDSS alerts than with no decision support system (adjusted 
odds ratio 3.18, 95% CI 1.02–9.87).
Interpretation—CDSS significantly improved the likelihood of appropriate and timely action on 
immunological treatment failure. We expect our findings will be generalisable to virological 
monitoring of patients with HIV receiving ART once countries implement the 2015 WHO 
recommendation to scale up viral load monitoring.
Funding—US President’s Emergency Plan for AIDS Relief (PEPFAR), through the US Centers 
for Disease Control and Prevention.
Introduction
At the end of 2014, 10.7 million people living with HIV in sub-Saharan Africa were 
receiving antiretroviral therapy (ART)—roughly 72% of the 14.9 million people receiving 
ART globally.1 In 2014, 1.9 million people were newly initiated on ART and this number is 
likely to increase as a result of the 2015 WHO guidelines for HIV treatment, which 
recommend treatment of all HIV-infected people, irrespective of their CD4 cell count.1,2 
With unprecedented ART scale-up comes a major challenge of early identification and 
management of individuals in whom first-line ART is unsuccessful.
First-line ART regimens comprise the standardised efficacious, cost-effective, widely 
available, and least toxic drugs. The consequences of ART failure include increased risk of 
HIV-associated complications, such as opportunistic infections, malignant diseases, and 
neurocognitive dysfunction. Studies done in sub-Saharan Africa show that 15–25% of 
people receiving ART experience conditions that define treatment failure.3–6 Although 
virological failure is the best predictor of ART failure, access to viral load monitoring for 
patients receiving ART remains restricted because of inadequate human capacity and 
laboratory infrastructure in resource-limited settings, especially in rural areas.6 Many rural 
clinics in sub-Saharan Africa therefore opt for WHO clinical staging and the widely 
available immunological monitoring based on CD4 cell measurement to monitor response to 
ART,5,7,8 despite immunological monitoring being an imperfect way to identify treatment 
failure.9
Most adults and children receiving ART in sub-Saharan Africa are enrolled in government-
owned HIV clinics, which are often busy and understaffed.10,11 The challenge of 
management of a chronic disease with linked data from repeated clinic visits in these 
circumstances has a negative effect on thorough clinical monitoring.6,12 Clinical decision 
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support systems (CDSS) are computer programs that apply knowledge, often in the form of 
sets of rules, to data stored in electronic health records to offer patient-specific and 
actionable recommendations to improve clinical decisions.13,14 CDSS applications 
communicate recommendations to clinicians through alerts and reminders, and have the 
potential to improve quality of care, patients’ safety, and outcomes in developed 
countries.15–17 Systematic reviews18,19 have shown that very few scientifically rigorous 
studies have been done in sub-Saharan Africa to show the effects of CDSS on clinical 
practice or health outcomes.
We did this study to establish whether a CDSS that supports detection of and recommends 
action on immunological treatment failure in patients with HIV on ART improves timely 
and appropriate action by clinicians.
Methods
Study design and participants
We did this prospective, cluster randomised controlled trial at HIV clinics in Siaya County, 
western Kenya. According to the Kenya HIV estimates report for 2013,20 the adult HIV 
prevalence in Siaya County was 23.7%, which is four times higher than the national 
prevalence. All clinics in the region, to which the Kenya Medical Research Institute 
(KEMRI) provides data management support, were invited to participate. The rural clinics 
were located within the health and demographic surveillance area where KEMRI does 
various public health studies.21 The health facilities comprised three types: dispensaries, 
categorised by the Kenyan Ministry of Health as level 2 facilities, which provide specific 
outpatient services focusing on disease prevention and basic curative care, and are headed 
by a nurse; health centres (level 3), which provide outpatient, maternal and child health, and 
some inpatient services, and are headed by a clinical officer; and district hospitals (level 4), 
which are principal referral facilities at the district level; offer a complete range of 
ambulatory, outpatient, and inpatient services; and are headed by a physician.22 We 
excluded health facilities if they did not have reliable electric power, a secure location for a 
computer, or permanent data clerks to help with the regular data management activities as 
required by the study protocol.
We enrolled adults and children (aged ≥18 months) with HIV who were eligible for, and 
receiving, ART at the participating clinics. ART eligibility was based on 2011 Kenyan 
Ministry of Health HIV treatment guidelines, which recommended initiation of ART in 
patients classified as WHO clinical stage III or IV (appendix p 1), irrespective of CD4 cell 
count, or as any WHO clinical stage with a CD4 count of less than 350 cells per μL.23 We 
included only patients who had at least two recorded CD4 cell counts on or after Jan 1, 2012 
(ie, 6 months before implementation of the CDSS), because at least two CD4 cell 
measurements are needed to define conditions for treatment failure. We did not include 
HIV-positive pregnant women because the CDSS intervention was not implemented at the 
maternal and child health clinic where pregnant women are followed up.
KEMRI staff responsible for primary data collection de-identified individual patient data 
before analysis, and we did not obtain informed consent because data could not be traced 
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back to individual patients. CDC and University of Amsterdam staff had no access to the 
patients or any information that would identify patients. The study was approved by the 
Associate Director for Science at the Center for Global Health of the US Centers for Disease 
Control and Prevention (CDC), and the institutional review board of KEMRI.
Randomisation and masking
The unit of randomisation was the health facility and not individual patients because all 
patients receiving HIV treatment at any participating clinic were given same level of 
treatment monitoring based on the type of electronic health record installed. The KEMRI 
data management team used block randomisation (block size of two) with a computer-
generated random number sequence to assign (1:1) eligible health facilities into two groups
—electronic health record either alone (control group) or with CDSS (intervention group)—
matched by Ministry of Health level and the number of patients enrolled in HIV care.24 For 
each level, whenever a clinic was randomly assigned to a group, a same-level clinic with the 
most similar number of patients enrolled was assigned to the opposite group. Health 
facilities participating in the study could not be masked to allocation because of the nature of 
the intervention.
Procedures
The health facilities transitioned from use of paper records to use of the Comprehensive 
Care Centre Patient Application Database (C-PAD) electronic health records for patient data 
management at varying times from July, 2009, to June, 2012. C-PAD was enhanced to 
include CDSS functionality and installed at the intervention sites in June, 2012. The 
electronic health records at control sites were upgraded to include CDSS at the end of the 
study in the event that positive associations were established. This process is part of the 
national scale-up of electronic health records in Kenya. For both the control and the 
intervention sites, clinicians recorded data on the paper-based patient encounter form (the 
so-called blue card) during the consultation, and the data clerk immediately entered this data 
into the computer. Laboratory results, including CD4 cell counts, were recorded on the blue 
card and entered into the electronic health records by the data clerks as soon as they were 
received from the laboratories. All CD4 cell counts were done at laboratories located within 
the participating health facilities or referral laboratories within Siaya County. The HIV care 
and treatment guidelines recommend that all HIV patients, irrespective of their WHO 
clinical stage, have a baseline and follow-up CD4 cell count.
Immunological treatment failure was defined in the 2011 Kenyan HIV treatment guidelines 
as any one of three conditions: a CD4 cell count less than the patient’s baseline 
measurement 6 months after initiation of therapy, a CD4 cell count less than 50% of peak 
measurement at any time after 6 months of treatment, or a CD4 cell count persistently less 
than 100 cells per μL after 12 months of treatment. Among children, immunological 
treatment failure was defined as a CD4 percentage of 10% or less or an absolute count of 
200 cells per μL or less 12 months or more after initiation of ART.23 The C-PAD electronic 
health record was designed to detect immunological treatment failure if any of the above 
conditions were encountered.
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Health facilities participating in the study had one of the two versions of C-PAD. The 
version installed at the intervention sites had a CDSS implemented with pop-up information 
about an individual patient whenever action is needed. An alert was generated when a 
patient had immunological treatment failure. In such cases, the CDSS offered the clinician 
advice about appropriate action such as adherence counselling for the patient, doing a repeat 
CD4 cell count, ordering a viral load measurement, substituting drug, or switching treatment 
regimen. The CDSS also generated a reminder about overdue CD4 count (ie, more than 6 
months after the last test, as defined in the Kenyan Ministry of Health HIV treatment 
guidelines).23 More than one action could be recommended (table 1). The condition causing 
the generation of the alert and the action recommended by the CDSS were printed out by the 
data clerk and filed on top of the patients’ notes for immediate clinical action either during 
the current or the next monthly visit. When clinicians deemed immediate action necessary, 
patients were called back to the clinic before their next appointment. Clinicians had the 
option to over-ride the decisions recommended by the CDSS, in which case they were asked 
to record their reason for not following the recommendation and this information was 
captured in the study case-report form.
The alerts were turned off in the version of C-PAD that supports standard care, which was 
installed at the control sites. Therefore, there were no alerts or recommendations and 
clinicians relied on weekly summary reports generated at patient level to make decisions 
about management, which is usual care since the implementation of electronic health 
records. The clinical staff and data clerks at the intervention sites were given practical 
training about the additional functionality and how to read the alerts and act on the 
recommendations. To avoid contamination, the control group received refresher training 
about use of the standard electronic health record and continued to provide care as usual, but 
received similar routine support visits by the KEMRI data management team as the 
intervention group. Training for both groups made reference to the HIV treatment guidelines 
whenever necessary and was in addition to the routine training provided by the Kenyan 
Ministry of Health. To generate data for alerts for analyses from the control sites, we 
retrospectively activated the CDSS alerts at the end of the study.
Outcomes
The primary outcome measure was the difference between groups in the proportion of 
patients who experienced any of the conditions that define immunological treatment failure 
and had a documented clinical action. Secondary outcomes were the effect of CDSS on time 
from detection of immunological treatment failure to clinical action, and time from ART 
initiation to first CD4 cell measurement. We qualitatively reviewed the most common 
reasons why clinicians ignore the recommendations of the CDSS, and time from ART 
eligibility to initiation of ART in patients who became eligible during the study period.
Statistical analysis
Sample-size calculations were based on the intention to include 20 facilities: ten facilities 
with electronic health records only or standard electronic health records and ten facilities 
with electronic health records and CDSS. A sample of 730 patients per group was required, 
with 80% power and a two-sided significant level of 0.05, to detect a difference between the 
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two groups, specifying proportions of patients with clinical action after immunological 
treatment failure of 35% in the control group and 75% in the intervention group. This 
sample size was calculated assuming a design effect of 2.0 (for the intrafacility correlation) 
and that 20% of patients would experience treatment failure.3,6 This resulted in an average 
of 73 sampled patients per clinic (1460/20) for each group of ten facilities. The sample-size 
calculation program was written in SAS statistical software (version 9.2), based on 
Rochon’s method.24
The data elements required for the analysis in this study were extracted directly from the 
electronic health record into analysis software. Because the data contained missing values 
for some variables, we performed Little’s test to assess whether data were missing 
completely at random.25 On the basis of the significant result obtained (p<0.0001), showing 
that missing data were not missing completely at random, we fitted a logistic regression 
model against the observed data to investigate whether data could be assumed to be missing 
at random. After confirmation that the data could be assumed to be missing at random, we 
used multiple imputation, which provides more efficient inference than complete case 
analysis when data are missing at random.26 We used the Markov chain Monte Carlo 
method to impute missing data. We also did complete case analysis and compared the results 
with those obtained with multiple imputation.
We calculated means with SDs and medians with IQRs to summarise continuous variables, 
and frequencies, proportions, and 95% CIs to summarise categorical variables. We used the 
Kruskal-Wallis test to compare medians. We used logistic regression models to assess the 
effect of CDSS on detection of and action on immunological treatment failure. Six patient-
level variables (age, sex, marital status, baseline CD4 cell count, WHO stage, and treatment 
regimen) and two centre-level variables (site type or level and duration of electronic health 
record use) were used as covariates to adjust for differences in case mix between 
intervention and control groups. We used generalised linear mixed models with random 
effects to analyse clustered data. Kaplan-Meier survival function plots and hazard ratios 
from the clustered Cox regression were used to measure statistical differences in the survival 
curves comparing time-to-event data and were expressed as a p value. Data were censored at 
the last follow-up visit. We did analyses with SAS (version 9.3) and Stata (version 13.0). 
This trial is registered with ClinicalTrials.gov, number NCT01634802.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Between Sept 1, 2012, and Jan 31, 2014, 13 clinics were randomly assigned to the control 
group (n=6) or the intervention group (n=7; figure 1). Data collection took 12 months at 
each site. 41 062 patients were enrolled in HIV care, of whom 19 662 (48%) patients were in 
control sites and 21 400 (52%) patients were in intervention sites. Of these patients, roughly 
half were eligible for and receiving ART (figure 1). Of the patients receiving ART, 1125 
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(11%) of 10 358 in the control group and 1342 (12%) of 10 991 in the intervention group 
had immunological treatment failure, of whom 332 (30%) and 737 (55%), respectively, had 
appropriate action taken (figure 1). Demographic and clinical characteristics of patients 
receiving ART were similar between groups, except for WHO clinical stage at enrolment in 
HIV care, for which more patients were classified in stages I and II in the control sites than 
in the intervention sites (table 2). Median age was 33 years (IQR 26–43), median CD4 cell 
count at enrolment into HIV care was 181 cells per μL (IQR 89–263), and most patients 
were in WHO clinical stage III at the time of enrolment in HIV care (table 2). The most 
common first-line regimens contained nevirapine (table 2). ART adherence at the last visit 
was 99% (table 2).
2467 (34%) of all 7192 alerts were indicative of immunological treatment failure. 
Appropriate action based on the national treatment guidelines was taken on 332 (29.5%, 
95% CI 26.8–32.2) of 1125 alerts in control sites compared with 737 (54.9%, 52.3–57.6) of 
1342 alerts in intervention sites. The unadjusted odds ratio (OR) for taking appropriate 
action at an intervention site was 3.22 (95% CI 1.02–10.22; table 3). After adjustment for 
patients’ age, sex, marital status, baseline CD4 cell count, WHO stage, and treatment 
regimen, the likelihood of clinicians taking appropriate action on conditions indicative of 
treatment failure was higher with use of CDSS than with no decision support system (OR 
3.18, 95% CI 1.02–9.87; table 3). The estimates obtained from multiple imputation and 
complete case analysis were similar for all variables (table 3, appendix p 2).
Of the 4376 recorded actions taken on patients who had HIV treatment failure, the most 
common were adherence counselling done (n=537), viral load ordered (n=571), alternative 
first-line drug substitution (n=73), repeat CD4 cell test (n=65), and a switch to second-line 
drugs (n=52). In some cases, more than one action was taken for the same patient.
The median time from alert to action was 47 days (95% CI 28–84) in the control group 
compared with 13 days (11–14) in the intervention group (p<0.0001; figure 2). 507 (90%) of 
556 ART-eligible patients in the control group and 669 (93%) of 723 in the intervention 
group initiated ART after CDSS implementation and had a recorded CD4 cell result. 4493 
(62.5%) of the 7192 alerts were indicative of cases for which the last CD4 cell test had been 
done more than 6 months previously. 162 (33.8%, 95% CI 24.9–44.9) of 480 patients in the 
control group, and 271 (41.5%, 32.2–52.4) of 652 patients in the intervention group, had 
CD4 cell counts done 6 months after ART initiation, as recommended in the HIV treatment 
guidelines. The median time from ART initiation to first CD4 cell count was 12.13 months 
(95% CI 6.17–not reached) in the control group and 6.76 months (5.13–11.23) in the 
intervention group (p<0.0001; figure 3).
In 1445 cases, clinicians did not act on the recommendation following an alert. In 1109 
(77%) of the cases in which the alerts were ignored, clinicians reported that the appropriate 
action (such as ordering adherence counselling) had been taken, but was not recorded in the 
patient charts. There were 225 (16%) cases in which the CD4 cell analyser was out of order 
or did not have reagents. In such cases, the recorded action was that a CD4 cell test had been 
ordered. In 15 (1%) cases, the clinician’s perception was that the CDSS alert was incorrectly 
raised because of errors in the data (eg, an incorrect CD4 cell value entered in the electronic 
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health record). In one case, a provider indicated that “it is possible to fail to act on an alert 
when the clinic is busy and there are many patients to attend to”.
120 patients were eligible for, but not receiving, ART in the control group compared with 37 
patients in the intervention group (figure 1). The CDSS generated 232 alerts for ART-
eligible patients who were not receiving ART, which accounted for 3.2% of all alerts 
generated. Overall, appropriate action, including pre-ART counselling or enrolment on 
ART, was taken on 103 (44.4%) of the alerts for ART-eligible patients not receiving ART. 
CDSS use was not significantly associated with appropriate initiation of eligible patients on 
ART (adjusted OR 1.04, 95% CI 0.41–2.68).
Discussion
Our results provide compelling evidence that a CDSS supports clinicians in timely detection 
and appropriate action on HIV treatment failure in conformity with HIV treatment 
guidelines. The odds of clinicians taking appropriate action on immunological treatment 
alerts were more than three times higher with CDSS than without a decision support system. 
Additionally, we recorded a 72% relative reduction in the median time taken from detection 
of conditions for treatment failure to appropriate action, and timely performance of CD4 cell 
counts, as recommended in the national HIV treatment guidelines.
Timely detection and action on HIV treatment failure can substantially reduce the risk of 
disease progression, drug resistance, and even death.23 Furthermore, early actions, such as 
ART adherence counselling or repeat or confirmatory CD4 cell counts, could help to 
identify patients in need of additional clinical support and could provide opportunities for 
prevention and timely diagnosis of opportunistic infections while ensuring timely switches 
to second-line treatment. This would ultimately improve quality of care, thereby reducing 
the need for more expensive second-line regimens that are also complex to administer and 
monitor. Second-line drugs cost about 110% more than first-line drugs; for example, the 
annual cost of first-line ART for an adult patient in Kenya in 2013 was US$338 compared 
with $716 for second-line treatment.27
Our findings also show that CDSS marginally improved timeliness of CD4 cell 
measurements, which is a crucial quality-of-care indicator for immunological response to 
treatment. Although the proportion of patients who had a CD4 cell test done 6 months after 
ART initiation was slightly higher in the CDSS group than in the control group, the 
difference was not statistically significant. Moreover, there was no significant association 
between use of CDSS and initiation of ART in eligible patients. This result is consistent 
with findings that attributed an absence of association to factors such as provider practice 
(clinician’s behaviour) and the patient’s own readiness to initiate ART.28 The overall 
improvement in quality of care shown in our study is consistent with many studies included 
in previous systematic reviews13,19 and adds to the few studies of CDSS done in resource-
constrained settings.29 The set of rules programmed in the CDSS to detect and recommend 
action on immunological treatment failure can also be applied to other laboratory test 
results, such as viral load. As routine viral load monitoring is implemented, CDSS could 
provide an opportunity for improved actions such as improved adherence, timely repeat viral 
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load testing, and treatment switches, thereby reducing the accumulation of drug-resistant 
mutations and improving clinical outcomes.
Because of an absence of reliable electric power, secure location for a computer, or 
permanent data clerks, seven of 20 invited HIV clinics could not be included in the study. 
However, at the remaining 13 sites, we were able to include 21 349 patients instead of the 
minimum required 1460 patients. The cluster randomised design of our study and the large 
sample size from multiple study sites minimised bias and improved the precision of 
estimates. As a sensitivity analysis, we used the generalised estimating equations approach 
to assess the magnitude of association between CDSS and appropriate action and, although 
the approach narrowed the confidence intervals, it did not qualitatively change the results, 
nor their significance. Doing both complete case and multiple imputation analyses was 
reassuring because the results from the two analyses were similar, with only slight variations 
in p values.
Notably, although the intervention was very effective, there is still much room (about 45%) 
for improvement in the actions taken on treatment failure. On the basis of studies done in 
sub-Saharan Africa, which estimated that 15–25% of HIV patients receiving ART have 
immunological treatment failure,3–6 the implication of no action taken on the alerts in 
Kenya, where about 744 000 patients with HIV were receiving ART at the end of 2014,30 is 
that at least 50 228 individuals could have immunological treatment failure with no action 
taken. Our study provided strong evidence that CDSS can significantly reduce this number, 
but there should be adequate capacity to act on the recommendations of the CDSS, including 
laboratory capacity to ensure timely conduct of CD4 cell tests and an optimum number of 
clinical staff with skills to act appropriately on immunological treatment failure. 
Additionally, investments are needed to improve health systems infrastructure, including 
reliable electric power, information and computer technology resources, and health workers’ 
information and computer technology capacity, in order to maximise on the benefits of 
CDSS on a wider scale.
Our study has some limitations. First, because of the high number of patients attending 
clinics with inadequate numbers of health workers, some actions might have been taken (eg, 
CD4 tests) but not recorded in the electronic health records, thereby potentially 
compromising data quality. This issue was particularly evident in control sites, where fewer 
alerts on overdue CD4 cell counts were noted despite regular supervision at all study sites to 
ensure high quality of data. This finding could indicate that CDSS alerts remind clinicians to 
record missing CD4 results. Second, clinical and nursing officers were frequently transferred 
to and from the study clinics, thereby introducing new health workers with no knowledge of 
the study. Ongoing training of clinical staff by the study team minimised the effect of such 
transfers. None of the staff was transferred from one study site to another, thereby 
eliminating any cross-over effect. Third, randomisation did not uniformly assign patients by 
severity of illness (WHO clinical stage). To correct for this irregularity, we adjusted for 
WHO stage in the multivariate analysis. The WHO HIV treatment guidelines launched in 
July, 2013, and the update released in September, 2015, recommend use of viral load tests to 
monitor patients’ response to HIV treatment,2,31 and Kenya is in the process of transitioning 
from immunological to virological monitoring of patients. The 2013 guidelines were 
Oluoch et al. Page 9













released in the last 6 months of the study and had not taken effect by January, 2014, when 
our data collection ended. Most countries in sub-Saharan Africa are beginning to roll out 
viral load monitoring as the preferred strategy for confirmation of ART treatment failure, 
but the operationalisation and feasibility of this approach still needs close monitoring and 
evaluation.
In conclusion, our study shows that CDSS can improve the likelihood of timely and 
appropriate action on immunological treatment failure in patients with HIV in resource-
limited settings. We expect that the associations shown will be generalisable to improvement 
of virological monitoring of patients receiving ART once countries implement the 
recommendations of the 2015 WHO HIV treatment guidelines to scale up viral load testing. 
Further studies are needed to assess the effect of CDSS on treatment outcomes such as viral 
suppression and survival in resource-limited settings.
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Evidence before this study
In 2012, we published a systematic review to identify original studies of the effect of 
clinical decision support systems (CDSS) on HIV care in resource-constrained settings. 
We searched on MEDLINE, Embase, CINAHL, and Global Health Library databases for 
original studies published before January, 2012. Our search criteria included MeSH terms 
relevant to HIV, electronic medical records, and decision support systems. Studies 
eligible for inclusion had to describe or evaluate implementation of an electronic medical 
record-based CDSS, include electronic medical records used to provide care to persons 
with an infectious or chronic disease (including HIV or tuberculosis), and have been done 
in a resource-constrained setting. Evidence from the above systematic review and more 
recently published studies and reviews in resource-constrained settings mainly report the 
effects of CDSS on process outcomes such as patient appointments, waiting time, and 
laboratory and pharmacy ordering time. Other outcomes of interest that have been 
associated with CDSS in resource-limited settings are adherence to guidelines, cost-
effectiveness, and data quality. Recent systematic reviews concur that most of the studies 
done in resource-limited settings are premature (ie, they describe effects of early 
implementations of electronic systems on health outcomes and processes) and of varying 
and overall low quality. Most of the studies have a weak study design or small sample 
size. Very few randomised controlled trials have been done in resource-limited settings to 
assess the effect of CDSS on quality of care and treatment outcomes. None of these trials 
measured outcomes on treatment failure in patients with chronic diseases in resource-
constrained settings. Because our systematic review was done more than 3 years ago, we 
did a new PubMed search on Oct 15, 2015, with MeSH terms “clinical decision support 
system” and “treatment failure”, which yielded 177 hits, of which 16 studies described 
the effect of CDSS on a clinical outcome. None of the 16 studies was done in a resource-
constrained setting.
Added value of this study
Our study contributes new knowledge by showing a strong association between an 
electronic medical record-based CDSS and appropriate action taken by clinicians on 
immunological treatment failure in HIV patients in resource-constrained settings. We 
also confirmed findings from previous studies with before-and-after study designs, which 
showed that CDSS is not associated with timely CD4 cell counts as recommended in the 
guidelines.
Implications of all available evidence
Although our main objective was to assess the effect of CDSS on appropriate action on 
immunological treatment failure in patients with HIV, the underlying model for 
longitudinal tracking of conditions that describe treatment failure and recommendation 
for appropriate action is applicable to other chronic diseases. We anticipate that the 
findings from our study will be generalisable to virological treatment failure because 
conditions defining virological treatment failure can be programmed in a CDSS in a 
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similar way as immunological treatment failure. However, more scientifically rigorous 
studies are needed to confirm the generalisability of these findings.
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Figure 1. Trial profile
ART=antiretroviral therapy.
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Time from immunological treatment failure to appropriate action in patients receiving 
antiretroviral therapy
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Time from initiation of antiretroviral therapy to first CD4 cell measurements
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Table 1
Condition and logic for alerts generated by the clinical decision support system
Alert generated Suggested actions by clinician
Ordering of CD4 cell count
Baseline CD4 T-cell count not available Please order baseline CD4 cell 
test
If result available, write in blue card
If result not available, consider the next immediate CD4 cell 
count as the baseline
If none is available, order CD4 test and give reasons why 
baseline CD4 was not available
The last CD4 cell count was done >6 
months before current visit date
The last CD4 test was done >6 
months ago
If result available, write in blue card
Indicated if CD4 test already reordered
Reorder CD4 test if result not available and not yet reordered
Treatment failure in adults
Fall in CD4 count to or to less than 
pretreatment baseline concentration, ≥12 
months after initiation of ART
Check for possible 
immunological treatment 
failure
Check on adherence and intervene
Check viral load and intervene
Order viral load test and intervene
Check change of drugs (substitution)
Check nutrition status and intervene, if needed
Query if there was a drug stock-out
Check if patient defaulted and intervene
Check if there is any social behaviour that may interfere with 
adherence—eg, alcoholism
Suspect immunological failure
Shorten the time to the next appointment for close monitoring
Do home visits by the staff to identify gaps at home
Decrease of ≥50% in CD4 count from on-
treatment peak value during the follow-up 
period




Persistent (two or more) CD4 count less 
than 100 cells per μL ≥12 months after 
initiation of ART




Assessment of opportunistic infections (eg, tuberculosis, 
Kaposi’s sarcoma, meningitis)
Treat opportunistic infections
Check nutrition status and intervene, if needed
ART eligibility for adults
CD4 count <350 cells per μL (irrespective 
of pregnancy) and not receiving ART
Patient is eligible for ART Prepare patient for initiation of ART, via adherence 
counselling, drug counselling to decrease pill burden
Give shorter appointment date
Initiate care
Check nutrition status and intervene, if needed
Patient co-infected with tuberculosis and 
HIV is not receiving ART
Patient is eligible for ART Change or update WHO staging
Isolate the patient or refer them to a tuberculosis clinic
Start on tuberculosis treatment immediately
Prepare the patient for ART Initiation within 2–8 weeks, after 
tuberculosis treatment has been tolerated
Check nutrition status and intervene
Order CD4 test
Teach the patient about tuberculosis infection control
Treatment failure in children
CD4 percentage of ≥10% or absolute 
count of ≤200 cells per μL, ≥12 months or 
more after initiation of ART
Check for possible 
immunological treatment 
failure
Thorough screening for opportunistic infections
Check or order viral load test and intervene
With viral load result, if virological failure switch drugs
Check on child adherence by querying caregiver and intervene
Shorten time to the next appointment
Check dosage of antiretroviral drugs against child’s weight
Check nutrition status and intervene, if needed
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Alert generated Suggested actions by clinician
Child aged >5 years with CD4 cell counts 
of ≤200 per μL, ≥12 months or more after 
initiation of ART




ART eligibility for children
Child aged <18 months, irrespective of 
CD4 cell counts and not receiving ART
Patient could be eligible for 
ART; please do confirmatory 
HIV DNA PCR test
Do antibody test, if positive, do PCR; if PCR is positive 
prepare for ART initiation and initiate when ready
Check nutrition status and intervene
Child aged 18–59 months with a CD4 
percentage of <25% or a CD4 count 
<1000 cells per μL and not receiving ART
Patient is eligible for ART but 
not on ART
Prepare and initiate
Check nutrition status and intervene, if needed
Child aged 5–12 years with a CD4 
percentage of <20% or a CD4 count <500 
cells per μL and not receiving ART
Patient is eligible for ART but 
not on ART
Prepare and initiate
Check nutrition status and intervene, if needed
Conditions listed are those that were implemented in the clinical decision support system and are not exhaustive of all conditions in the clinical 
guidelines. ART=antiretroviral therapy.
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Table 2
Baseline characteristics
Control (n=19 662) Intervention (n=21 400) Total (n=41 062)
Age group (years)
<15    1718 (8.7%, 8.3–9.1)    1674 (7.8%, 7.5–8.2)    3392 (8.3%, 8–8.5)
15–24    3899 (19.8%, 19.3–20.4)    3563 (16.7%, 16.2–17.1)    7462 (18.2%, 17.8–18.5)
25–49 12 264 (62.4%, 61.7–63.1) 13 749 (64.2%, 63.6–64.9) 26 013 (63.4%, 62.9–63.8)
≥50    1781 (9.1%, 8.7–9.5)    2414 (11.3%, 10.9–11.7)    4195 (10.2%, 9.9–10.5)
Sex
Male    6676 (34.0%, 33.3–34.6)    7661 (35.8%, 35.2–36.4) 14 337 (34.9%, 34.5–35.4)
Female 12 986 (66.0%, 65.4–66.7) 13 739 (64.2%, 63.6–64.8) 26 725 (65.1%, 64.6–65.5)
Marital status
Married 10 759 (54.7%, 54–55.4) 11 213 (52.4%, 51.7–53.1) 21 972 (53.5%, 53–54)
Divorced or separated    1427 (7.3%, 6.9–7.6)    1827 (8.5%, 8.2–8.9)    3254 (7.9%, 7.7–8.2)
Widow    3791 (19.3%, 18.7–19.8)    4216 (19.7%, 19.2–20.2)    8007 (19.5%, 19.1–19.9)
Single    3685 (18.7%, 18.2–19.3)    4144 (19.4%, 18.8–19.9)    7829 (19.1%, 18.7–19.4)
Baseline CD4 category (cells per μL)
<350 16 893 (85.9%, 85.4–86.4) 18 690 (87.3%, 86.9–87.8) 35 583 (86.7%, 86.3–87)
350–500    2489 (12.7%, 12.2–13.1)    2504 (11.7%, 11.3–12.1)    4993 (12.2%, 11.8–12.5)
>500      280 (1.4%, 1.3–1.6)      206 (1%, 0.8–1.1)      486 (1.2%, 1.1–1.3)
WHO stage at enrolment
I    5936 (30.2%, 29.6–30.8)    4941 (23.1%, 22.5–23.7) 10 877 (26.5%, 26.1–26.9)
II    6295 (32%, 31.4–32.7)    6027 (28.2%, 27.6–28.8) 12 322 (30%, 29.6–30.5)
III    6950 (35.3%, 34.7–36)    9759 (45.6%, 44.9–46.3) 16 710 (40.7%, 40.2–41.2)
IV      480 2.4%, 2.2–2.7)      673 (3.1%, 2.9–3.4)    1153 (2.8%, 2.6–3)
Transfer out
No 17 289 (87.9%, 87.5–88.4) 19 006 (88.8%, 88.4–89.2) 36 295 (88.4%, 88.1–88.7)
Yes    2373 (12%, 11.6–12.5)    2394 (11.2%, 10.8–11.6)    4767 (11.6%, 11.3–11.9)
First-line regimen
Nevirapine    9097 (86.3%, 85.7–87)    9438 (85%, 84.4–85.7) 18 534 (85.7%, 85.2–86.1)
Efavirenz    1399 (13.3%, 12.6–13.9)    1588 (14.3%, 13.7–15)    2986 (13.8%, 13.3–14.3)
Other        45 (0.4%, 0.3–0.5)        74 (0.7%, 0.5–0.8)      118 (0.5%, 0.4–0.6)
ART adherence at last visit
Satisfactory 10 525 (99.9%, 99.8–99.9) 11 079 (99.8%, 99.7–99.9) 21 604 (99.8%, 99.8–99.9)
Unsatisfactory        15 (0.1%, 0.1–0.2)        20 (0.2%, 0.1–0.3)        35 (0.2%, 0.1–0.2)
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Data are n (%, 95% CI). ART=antiretroviral therapy.
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Table 3
Association between clinical decision support system alerts and appropriate action on treatment
Unadjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI) p value
Site status
Control 1   ·· 1   ··
Intervention 3.22 (1.02–10.22)   0.047 3.18 (1.02–9.87)   0.05
Age group (years)
<15 0.90 (0.74–1.08)   0.25 0.97 (0.78–1.21)   0.81
15–24 1.25 (0.91–1.74)   0.17 1.38 (1.24–1.53) <0.0001
25–49 1.32 (1.18–1.46) <0.0001 1.47 (1.08–1.99)   0.013
≥50 1   ·· 1   ··
Sex
Male 1.11 (1.04–1.19)   0.0016 1.16 (1.09–1.24) <0.0001
Female 1   ·· 1   ··
Marital status
Married 1.21 (0.98–1.51)   0.077 ··   ··
Divorced or separated 1.31 (1.14–1.52)   0.0003 ··   ··
Widow 1   ·· ··   ··
Single 0.93 (0.84–1.03)   0.18 ··   ··
WHO stage
I 1   ·· 1   ··
II 1.67 (1.34–2.09) <0.0001 1.62 (1.58–1.67) <0.0001
III 1.68 (1.57–1.80) <0.0001 1.64 (1.30–2.06) <0.0001
IV 1.47 (0.91–2.40)   0.12 1.37 (0.89–2.12)   0.15
Baseline CD4 category (cells per μL)
<350 3.27 (2.87–3.73) <0.0001 ··   ··
350–500 2.85 (1.69–4.82) <0.0001 ··   ··
>500 1   ·· ··   ··
Transfer out
No 1.25 (0.79–1.97)   0.34 ··   ··
Yes 1   ·· ··   ··
First-line regimen
Nevirapine 1.85 (1.37–2.52) <0.0001 ··   ··
Efavirenz 1.41 (0.89–2.22)   0.14 ··   ··
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Unadjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI) p value
ART adherence
Satisfactory 1.59 (0.67–3.79)   0.29 ··   ··
Unsatisfactory 1   ·· ··   ··
ART=antiretroviral therapy.
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